Dimensional Fund Advisors LP Boosts Holdings in Progyny, Inc. (NASDAQ:PGNY)

Dimensional Fund Advisors LP boosted its stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 6.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,186,027 shares of the company's stock after buying an additional 74,740 shares during the period. Dimensional Fund Advisors LP owned approximately 1.39% of Progyny worth $20,458,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in shares of Progyny by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 8,692,132 shares of the company's stock worth $149,939,000 after purchasing an additional 48,271 shares during the last quarter. Pacer Advisors Inc. raised its holdings in Progyny by 47.5% in the fourth quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company's stock worth $63,414,000 after buying an additional 1,183,558 shares during the last quarter. River Road Asset Management LLC bought a new position in shares of Progyny in the fourth quarter worth approximately $25,529,000. Fort Washington Investment Advisors Inc. OH lifted its stake in shares of Progyny by 90.1% in the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock worth $25,319,000 after buying an additional 695,740 shares in the last quarter. Finally, Barclays PLC grew its holdings in shares of Progyny by 95.7% during the fourth quarter. Barclays PLC now owns 1,382,205 shares of the company's stock valued at $23,843,000 after buying an additional 676,048 shares during the last quarter. Hedge funds and other institutional investors own 94.93% of the company's stock.

Progyny Stock Down 9.3 %

PGNY traded down $2.17 during trading on Friday, hitting $21.20. The company's stock had a trading volume of 3,566,405 shares, compared to its average volume of 1,722,248. The business's 50 day simple moving average is $21.95 and its 200-day simple moving average is $19.54. The firm has a market cap of $1.82 billion, a PE ratio of 36.55, a P/E/G ratio of 2.39 and a beta of 1.37. Progyny, Inc. has a one year low of $13.39 and a one year high of $30.42.

Progyny (NASDAQ:PGNY - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.45 by ($0.28). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The company had revenue of $324.04 million for the quarter, compared to analysts' expectations of $307.86 million. During the same quarter last year, the firm posted $0.17 earnings per share. Progyny's revenue for the quarter was up 16.5% on a year-over-year basis. Equities research analysts expect that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. BTIG Research upgraded shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price objective for the company in a report on Monday, March 31st. Canaccord Genuity Group boosted their price target on Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a research note on Friday, February 28th. Bank of America lifted their price objective on Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a report on Tuesday, February 11th. Finally, JPMorgan Chase & Co. upped their target price on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Progyny presently has a consensus rating of "Hold" and an average target price of $23.64.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.